**In Reply to Helms:** In the article by Helms et al., Helms concludes that infections with *Salmonella* Typhimurium strains resistant to ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline (hereafter referred to as penta-resistant) were associated with higher death rates than infections with non--penta-resistant *S.* Typhimurium. Helms also concluded that infections with quinolone-resistant (nalidixine-resistant) *S.* Typhimurium were associated with higher death rates than quinolone-susceptible *S.* Typhimurium ([@R1]).

[Table 2](#T2){ref-type="table"} in Helms' article provides information that enables close scrutiny of this conclusion and comparison of the excess mortality associated with penta-resistant, quinolone-susceptible *S.* Typhimurium with the excess mortality of non--penta-resistant *S.* Typhimurium ([@R1]). In this letter, the Table is based on the original table. However, two additional comparisons have been added: the p values, which are not based on the data but are approximations based on the parameters in the table.

###### Two-year relative death rate of patients infected with *Salmonella* Typhimurium, by antimicrobial susceptibility pattern. Registry linkage study including 2,047 patients and a random matched sample of 20,456 people from the Danish general population

                                 Resistant   Susceptible^a^                                  
  ------------------------------ ----------- ----------------- ---------- ------------------ ------
  Resistant to [\>]{.ul}1 drug   13/393      3.5 (1.7-7.2)     28/953     2.3 (1.5-3.5)      0.86
  Ampicillin                     16/347      5.1 (2.6-10.2)    46/1,654   2.1 (1.5-3.0)      0.21
  Chloramphenicol                13/458      2.1 (1.1-4.1)     43/1,700   1.9 (1.4-2.8)      0.01
  Streptomycin                   31/969      2.5 (1.6-3.9)     46/1,589   2.4 (1.7-3.4)      0.76
  Sulfonamides                   15/513      2.2 (1.2-4.1)     28/1,078   2.1 (1.4-3.3)      0.60
  Tetracycline                   3/108                         44/1,534   2.4 (1.7-3.4)      0.85
  Kanamycin                      5/83        10.3(2.8-37.8)    23/1,018   3.9 (2.2-6.7)      
  Quinolone                      12/283      4.8 (2.2-10.5)    54/1,964   2.1 (1.6-3.0)      0.02
  R-type ACSSuT                  5/40        13.1 (3.3-51.9)   47/1,764   2.1 (1.5-2.9)      0.06
  R-type ACSSuTNx                5/40        13.1 (3.3-51.9)   7/243^e^   2.9^­^ (1.1-7.9)   0.09
                                                                                             
                                                                                             
                                                                                             

^a^Susceptible refers to strains susceptible to the given antimicrobial drugs or combination of antimicrobial drugs; first cell refers to pansusceptible strains. ^b^Death rate relative to the general population, as estimated by conditional proportional hazards regression analysis, controlling for underlying illness; RR=rate ratio. ^c^CI=confidence interval. ^d^p-value for test of homogeneity, i.e., RR for resistant being the same as for susceptible strains. ^e^Strains with R-type ACSSuT, but quinolone sensitve.

The conclusion is that only quinolone resistance is associated with excess mortality compared with nonresistant isolates. Penta-resistant, quinolone-susceptible *S.* Typhimurium has a risk ratio of 2.9 (1.1 to 7.9) compared to the ratio of non--penta-resistant isolates 2.1 (1.5 to 2.9). When these figures are compared, the approximate p value is 0.55, which, of course, is far from being significant. Thus, on the basis of the article by Helms, penta resistance may not pose a greater threat to human health than non--penta resistance. However, the measured effect of penta resistance is achieved by the inclusion of quinolone-resistant *S.* Typhimurium in the group.

###### Table showing additional comparisons (1)^a^

                                     Resistant   Susceptible          p value                          
  ---------------------------------- ----------- -------------------- ---------- --------------------- ----------
  Penta with and without quinolone   12/283      4.8 (2.2 to 10.5)    47/1,764   2.1 (1.5 to 2.9)      0,06
  Penta with quinolone               5/40        13.1 (3.3 to 51.9)   47/1,764   2.1 (1.5 to 2.9)^c^   0,01^d^
  Penta without quinolone            7/243       2.9 (1.1 to 7.9)     47/1764    2.1 (1.5 to 2.9)^c^   0,55c^d^

^a^RR, relative risk; CI, confidence interval. ^b^Adjusted for coexisting conditions. ^c^Compared to the non-penta group. ^d^Approximations based on the parameters from the table.
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